Whitney Limm

Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches

Only 10% to 20% of patients with primary and colorectal metastatic liver tumors are candidates for curative surgical resection. Even after curative treatment, tumors recur commonly in the liver. As a less invasive therapy, radiofrequency thermal ablation (RFA) of primary, metastatic, and recurrent liver tumors was performed under percutaneous, laparoscopic, or open intraoperative ultrasound guidance. The safety and local control efficacy of RFA were investigated. RFA was performed mostly in patients with unresectable hepatomas or metastatic liver tumors. Patients with large tumors, major vessel or bile duct invasion, limited extrahepatic metastases, or liver dysfunction were not excluded. An RFA system with a 15-gauge electrode-cannula with four-pronged retractable needles was used. All patients were followed for more than 8 months to assess morbidity and mortality, and to determine tumor recurrence. Sixty RFA operations were performed in 46 patients: 11 patients underwent repeat RFA once or twice. A total of 204 tumors were treated: 70 hepatomas and 134 metastatic tumors. Tumor size ranged from 5 mm to 180 mm (mean 36 mm). RFA was performed in 29 operations for 81 tumors percutaneously, in seven operations for 14 tumors laparoscopically, and in 24 operations for 109 tumors by open surgery. Combined colorectal resection was carried out in five operations and combined hepatic resection was carried out in three operations. There was one death (1.7%) from liver failure, and there were three major complications (5%): one case of bile leakage and two biliary strictures due to thermal injury. There were no intra-abdominal infectious or bleeding complications. The length of hospital stay ranged from 0 to 2, 1 to 3, and 4 to 7 days for percutaneous, laparoscopic, and open surgical RFA, respectively. During a mean follow-up period of 20.5 months, local tumor recurrence at the RFA site was diagnosed in 18 (8.8%) of 204 tumors. The risk factors for local recurrence included large tumor size and major vessel invasion: recurrence rates for tumors less than 4 cm, 4 to 10 cm, and greater than 10 cm, and for those with vessel invasion were 3.3%, 14.7%) 50%) and 47.8%) respectively. Ten of 18 tumors recurring locally were retreated by RFA, and eight of them showed no further recurrence. Ultrasound-guided RFA is a relatively safe, well-tolerated, and versatile treatment option that offers excellent local control of primary and metastatic liver tumors. The appropriate use of percutaneous, laparoscopic, and open surgical RFA is beneficial in the management of patients with liver tumors in a variety of situations.

Liver transplant for hepatocellular cancer: a treatment for the select few

Abstract:  Hepatocellular cancer (HCC) is increasing in incidence and liver transplant (LT) is likely the best treatment for long‐term survival and decreased recurrence in those with localized disease. Optimal treatment for HCC is limited by advanced stage at presentation and available donors. We retrospectively reviewed 232 cases of HCC from 1993 to 2002 referred to our medical center, which also has the only transplant program in the state. Demographic data, risk factors, stage, previous treatment, candidacy for LT, and outcome were noted. Stage distribution was as follows: stage I – nine patients, II – 115 patients, III – 31 patients, and IV – 76 patients. Mean age was 61.1 yr and 62 patients were over the age of 70 yr. Thirty‐five patients (15.1%) were offered LT evaluation. Nineteen patients (8.2%) eventually underwent LT, five are currently on a transplant waiting list, three were on a list but removed due to death or progression of disease, six were evaluated but not listed, and two refused evaluation. Five patients were transplanted because implementation of the Model of End‐stage Liver Disease (MELD) system for organ allocation. Of 19 patients who underwent LT, 14 are still alive 3–52 months post‐transplant, three developed recurrent HCC, and two died of lung cancer. Although LT may be the best treatment for HCC, a relatively small number of patients (15%) will qualify for this therapy. About half of those who qualify will actually undergo LT. This further emphasizes the need for other strategies such as vaccination, chemoprevention, and early detection to improve survival from HCC.

High- and low-dose superoxide dismutase plus catalase does not reduce myocardial infarct size in a subhuman primate model

Oxygen free radical scavengers have been found to decrease infarct size in dogs subjected to myocardial ischemia-reperfusion injury. A baboon open-chest model was used to determine if superoxide dismutase (SOD), an oxygen free radical scavenger, together with catalase would be equally effective in subhuman primates (baboons). The left anterior descending coronary artery (LAD) was ligated for 2 hours. Before reperfusion, the animals received the following: Group 1 (low-dose SOD/catalase; n = 5) received 15,000 IU/kg of SOD and 55,000 IU/kg of catalase IV over 1 hour, 15 minutes before reperfusion. Group 2 (high-dose human SOD [h-SOD]/catalase; n = 5) received an intraatrial bolus of 400,000 IU of recombinant h-SOD and 27,500 IU/kg of catalase over 30 seconds, followed by 300,000 IU of h-SOD and 55,000 IU/kg of catalase over 1 hour, beginning 15 seconds before reperfusion. Group 3 (n = 8) were control animals. Baboons were put to death 22 hours after reperfusion. Their hearts were excised and sectioned after the perfusion bed distal to the site of ligation was delineated with microvascular dye. The infarct zone was determined histologically. Areas of the perfusion bed and infarct zone were measured by planimetry. Infarct size did not differ significantly between the three groups: control, 66 +/- 7%; low-dose SOD/catalase, 68 +/- 5%; and high-dose h-SOD/catalase, 74 +/- 4%. In this model, high- and low-dose SOD with catalase did not result in any significant reduction in infarct size.

What is the likelihood of requiring contralateral inguinal hernia repair after unilateral repair

BACKGROUND Factors that predispose patients to the development of inguinal hernias will persist after repair. This study aimed to determine the incidence of future contralateral hernia repair. METHODS We performed a retrospective review of a non-Medicare claims database (1999-2009) to identify patients billed for 2 asynchronous initial inguinal hernia repairs. RESULTS In this database, 7,050 patients were followed up for a mean of 3.6 years, 272 patients required a contralateral hernia repair. The mean time between hernia repairs was 2.9 years and the same surgeon repaired both hernias in 67.6%. Fifteen patients had incarcerated contralateral hernias (5.5%). Patients who required contralateral repairs were older (62.2 vs 59.6 y; P = .014) and had prostate disease (odds ratio, 1.45; P = .0001). The risk of needing a contralateral inguinal hernia repair at 5 and 10 years of follow-up evaluation was 2.5% and 3.8%, respectively. CONCLUSIONS Despite a reported 8% to 22% incidence of clinically unsuspected contralateral inguinal hernia, the likelihood of undergoing contralateral repair within 10 years is low at 3.8%.